Complications after radical gastrectomy following neoadjuvant chemotherapy for gastric cancer        LI Zi-yu, JI Xin, JI Jia-fu. Department of Gastrointestinal Surgery, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing100142, China
Corresponding author: LI Zi-yu, E-mail: ligregory369@hotmail.com
Abstract    The concept of neoadjuvant chemotherapy has been widely accepted recently for the benefit of increasing the R0 resection rate and the long-term survival in patients with gastric cancer. To date, owing to the results of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial, perioperative chemotherapy for locally advanced resectable gastric cancer has become a grade A recommendation. There are limited data available regarding postoperative morbidity and mortality in patients performed neoadjuvant chemotherapy for gastric cancer. If neoadjuvant chemotherapy is going to be considered as a therapeutic option in patients with locally advanced gastric cancer, it is necessary to verify that it can be delivered safely without an increase in postoperative morbidity and mortality.